C-UPILTreefrog Therapeutics
iPS-derived cell therapies, C-Stem, 3D microtissue
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-UPIL
C-UPILC-UPILiPS-derived cell therapies, C-Stem, 3D microtissue
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Avec Kévin Alessandri, cofondateur et VP US de TreeFrog. tech&fest 2025 est le grand festival de l'innovation organisé par Le Dauphiné Libéré qui s'est tenu les mercredi 5 et jeudi 6 février à Alpexpo Grenoble. ➡️ LinkedIn : https://www.linkedin.com/company/tech-fest/ ➡️ Instagram : https://www.instagram.com/techandfest/ ➡️ tech&fest : https://www.tech-fest.fr/ ➡️ Le Dauphiné Libéré : https://www.ledauphine.com/
Retrouvez l'intervention de Maxime FEYEUX, null de TreeFrog Therapeutics, Kevin ALESSANDRI, Cofondateur, VP US et CTO de TreeFrog Therapeutics sur STUDIO BANG à l'Accor Arena à l'occasion de BIG 2024, le plus grand rassemblement business d'Europe organisé par Bpifrance. Kevin Alessandri, vice-président US de TreeFrog Therapeutics, et Maxime Feyeux, cofondateur, ont développé une technologie révolutionnaire en thérapie cellulaire. Leur approche consiste à mettre les cellules au centre de la production, permettant aux cellules de se produire elles-mêmes. Ils ont été soutenus par Bpifrance et ont réussi à industrialiser leur solution. Leur ambition est de transformer l'industrie en utilisant des machines vivantes pour produire des médicaments. Ils ont quitté le laboratoire pour devenir entrepreneurs, cherchant à avoir un impact concret dans la société. Ce résumé a été généré par une IA. #Biotechnologie #Innovation #Entrepreneuriat #ThérapieCellulaire #SuccessStory #Bpifrance #Big #Big
Retrouvez l'intervention de Kevin ALESSANDRI sur BANG à l'Accor Arena à l'occasion de BIG 2024, le plus grand rassemblement business d'Europe organisé par Bpifrance. Une entreprise appelée TreeFrog Therapeutics, fondée par Kevin ALESSANDRI , se concentre sur la thérapie cellulaire. Kevin ALESSANDRI discute de l'évolution de la technologie et de son intégration avec la nature. Il met en avant le potentiel des avancées récentes, telles que les vaccins ARN et l'immuno-oncologie, pour transformer les soins de santé. TreeFrog Therapeutics adopte une approche industrielle novatrice en laissant les cellules s'auto-organiser pour créer des thérapies cellulaires. Kevin ALESSANDRI souligne que ces avancées contribuent à améliorer la qualité de vie des patients, tout en soulignant le passage de l'ère du silicium à l'ère du carbone, symbolisant le lien entre la technologie et la vie. Ce résumé a été généré par une IA #ThérapieCellulaire #InnovationMédicale #ProgrèsTechnologique #SantéPublique
Kevin Alessandri, co-founder of TreeFrog Therapeutics, introduces stem cell therapy and TreeFrog's approach to bringing Cell Therapy for All.
For International Women’s Day 2024, we look to the future and the next generation. We asked some of our Froggies what they hope for their daughters when they grow up! Thanks to Laura OUDJEDI, Fabien MONCAUBEIG, Lucie MANACHE-ALBERICI, Beatrice LEGAS, Michael LANERO FIDALGO and Kévin ALESSANDRI.
Did you know that March 20 is World Frog Day? 🐸 We thought it was the perfect day to share with you the origin of our name TreeFrog Therapeutics. Enjoy the explanation from our two co-founders Kévin Alessandri and Maxime Feyeux. Happy Frog Day!
TreeFrog dans le classement FrenchTech120 ! Quelle trajectoire ? Quels jalons à venir ? Quel impact en France ? 2 min avec Jean-Luc Treillou, co-fondateur de TreeFrog Therapeutics.
Cofondateur et président du conseil d'administrateur de TreeFrog Therapeutics, administrateur indépendant au sein de plusieurs startups, cofondateur d'Ysopia Bioscience... Jean-Luc Treillou a l'habitude de jongler avec plusieurs casquettes. Dans cet épisode n°31 de la French Tech Box, ce multi-entrepreneur chevronné évoque sa manière de fonctionner et de s'impliquer dans de nombreux projets entrepreneuriaux. "Ce qui m'intéresse, c'est de faire partie d'une aventure collective qui met les choses en mouvement et d'apporter une pierre qui va avoir un impact", explique-t-il. Il aborde également le sujet de l'égo et la nécessité de prendre du temps pour souffler.
TreeFrog Therapeutics' co-founder Kevin Alessandri will move from Bordeaux, France, to Boston in early 2022 to create a technological hub aimed at driving the adoption of the C-Stem technology in the US. What's his vision ? Why Boston ? What will TreeFrog do in the US ?
Kevin Alessandri et Maxime Feyeux, Co-fondateurs de TreeFrog Therapeutics sont les lauréats du Prix de la Start-Up de l’Année 2021 pour la région Nouvelle-Aquitaine. TreeFrog Therapeutics est une jeune start-up fondée par Kévin Alessandri et Maxime Feyeux en 2018 afin de rendre accessible la thérapie cellulaire au plus grand nombre. Elle a combiné les compétences biologiques cellulaires de Maxime et technologiques de Kevin, afin d’inventer la technologie C-stem : l’encapsulation de cellules souches permettant de les produire à grande échelle et de révolutionner la thérapie cellulaire. Les applications médicales de cette plateforme technologique sont donc infinies et permettent à Treefrog d’envisager un chiffre d’affaires de plusieurs dizaines de millions d’euros d’ici 2 à 3 ans. Une première levée de fonds de 7 millions d’euros a déjà été réalisée en 2018. Le moteur de ces deux entrepreneurs, au-delà de ces perspectives de rentabilité, demeure l’envie de « guérir le monde ». Réservez
What's the story behind TreeFrog ? 3 minutes with the co-founders of TreeFrog Therapeutics, Kevin Alessandri, PhD, an expert in cell encapsulation microfluidics, and Maxime Feyeux, PhD, stem cell biologist.
Kevin Alessandri, Ph.D., CEO and Chief Technology Officer Bordeaux, France (Private)
Following an international career in the pharma industry (GSK, Sanofi, Oenobiol), Jean-Luc co-founded microbiome company LNC therapeutics in 2011, eventually raising 16.5M€ as CEO & Chairman. In 2018, he co-founded TreeFrog Therapeutics, taking charge of governance and investor relations as Chairman of the Board.
Better cells, Better Therapies https://treefrog.fr TreeFrog Therapeutics mass-produces stem cells and organoids to enable the development of cell therapies for all. Interview of Kevin Alessandri, Maxime Feyeux and Erwan Bézard. The cells we produce can be used to treat neurodegenerative diseases such as Parkinson and Huntington's disease. TreeFrog produit en masse des cellules souches et des organises pour permettre le développement de thérapies cellulaires pour tous. interview de Kevin Alessandri, Maxime Feyeux et Erwan Bézard. Les cellules que nous produisons peuvent être utilisées pour traiter la maladie de Parkinson ou d'Huntington par exemple.
TreeFrog Therapeutics reinforces Executive Committee with three new members - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR TreeFrog Therapeutics reinforces Executive Committee with three new members Jens Schröder, Chief Medical Officer Rachel Mooney, Chief Communications Officer Jaime Arango, Chief Financial Officer BORDEAUX, France / November 9th, 2023 – TreeFrog Therapeutics , a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, tod
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth Submit a Release Home All ESG Health Technology Finance Contributors Sub Menu Submit a Release main-search-pop Main menu TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth Contributed by: Business Wire Logo Images Mark Rothera, CEO TreeFrog Therapeutics Tags Health Other Health Other Science Resear … S CELL THERAPIES FOR TYPE 1 DIABETES TREEFROG THERAPEUTICS PICKS-UP BEST POSTER AWARD AT THE INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY (ISCT) ANNUAL MEETING FOR THEIR CELL THERAPY PROGRAM IN PARKINSON'S DISEASE TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S CELL THERAPY PROGRAM AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth TreeFrog Publishes Results of First Successful Bioproduct … e All ESG Health Technology Finance Contributors Press Release Hub Our Services Submit a Release Websites PA Media Group PA Mediapoint Distribution Packages © PA Media Group. 2026 Terms of Use Privacy Policy Contact Us
McDermott Advises TreeFrog Therapeutics on Licensing Agreement Skip to main content People Capabilities Capabilities Services Services Antitrust Business Restructuring Corporate & Transactional Crisis Management Data, Privacy & Cybersecurity Employee Benefits & Executive Compensation Employment Global White-Collar & Government Investigations Government & Lobbying Strategies Government Contracts Intellectual Property International Trade Investment Management Litigation & Dispute Resolution Private Client Real Estate Shareholder Activism Strategic Solutions Sustainability
Coulter Partners Places Mark Rothera as TreeFrog Therapeutics CEO | Coulter Partners posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig … ct of computational biology skills. The ability to analyse multi-omic datasets, apply machine learning to biological questions, and translate computational findings into testable hypotheses has become fundamental to drug discovery. These capabilities are no longer specialised tools. They’re core competencies for modern biologists working at the interface of computation and experimental validation. Congratulations to Ben Thomas , Dermot Tierney , and the entire AMPLY team. You … company, raised $27M in a Series B financing from new investors Chugai Venture Fund (CVF) and the Gates Foundation , bringing total capital raised to more than $45M. The company is an AI-driven drug discovery spinout from Duke University and Toyota Technological Institute at Chicago (TTIC) that uses its BEYOND generative-chemistry platform to design first- and best-in-class therapies. Ten63 is advancing an internal oncology pipeline while pursuing selective partnerships acro
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes - Treefrog Therapeutics | Elsy Boglioli Hofman LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your s
Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic
Women advancing Cell Therapy for All at TreeFrog Therapeutics: #2 Lucie, Analytical Development Engineer | Mark Rothera MA MBA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … unsung hero of DNA’s discovery. 🧪 Marie Curie – The first woman to win a Nobel Prize for her work in radioactivity. 🧬 Jennifer Doudna & Emmanuelle Charpentier – The pioneers of CRISPR gene-editing. 💊 Katalin Karikó – A key figure behind mRNA vaccine technology. Their discoveries have saved lives, reshaped medicine, and expanded our understanding of the world—but the work isn’t done. Women in STEM still face barriers, and representation matters. Let’s continue breaking … on female controlled non hormonal contraception. They competed for a $2 Million grant and support from the Gates Foundation . The room was focused. Scientists, investors, industry leaders, and global partners asked hard questions. The goal was clear. Build better options for women. Video https://lnkd.in/dPzCb8Zp Press release https://lnkd.in/dK4UwDyW #Femtech is entering a new phase. #Deeptech is accelerating it. In the Deep Tech report I co wrote with Hello Tomorrow , we sho … modeling, or soft matter, we invite you to share your expertise. Learn more and submit your research here: https://lnkd.in/gSwuscVk #InternationalWomensDay #IWD2026 #Biophysics #WomenInScience #STEM #AcademicPublishing 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in BioGrad 4,771 followers 3mo Report this post It’s been a few weeks since International Women and Girls in Science Day… and awareness alone isn’t enough. So no, we’re not going to li
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth | Business Wire Sök nyheter Abonnera Sök pressrum Om tjänsten Bli kund TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth 16.12.2025 09:05:00 CET | Business Wire | Press Release Share TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprie … today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every securi … deling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility 26.6.2026 22:30:00 CEST | Press Release Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan … sponsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve custom … nance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S CELL THERAPY PROGRAM AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery … first-in-world technology, C-Stem™ and with this now have the first successful application of the 3D format microtissue that delivers efficacy in pre-clinical models. The results speak for themselves with full behavioral recovery observed by 16 weeks after transplantation using the cryopreserved 3D cell format. We look forward to continuing to bring our data to the scientific community as we advance our program" said Kevin Alessandri , Chief Technology Officer, TreeFro … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Kevin ALESSANDRI Accueil Le LIVE Intervenants Partenaires Programme lesdeeptech.fr Connexion KA Kevin ALESSANDRI TREEFROG THERAPEUTICS CTO et cofondateur Biographie La thérapie cellulaire pour tous Normalien et docteur en physique, il rencontre Maxime Feyeux, également normalien et docteur en neurobiologie après leur thèse, en 2014 à l’université de Genève. Ensemble, ils ont l’idée de créer une entreprise autour de l’industrialisation des thérapies cellulaires. Le pari est risqué, car la production de cellules-souches doit répondre à des enjeux de taille : être capable de produire des cellules
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S CELL THERAPY PROGRAM AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING Accessibility Statement Skip Navigation Resources Investor Relations Journalists Webcasts Français --> Français my CNW Login Register Client Login PR Newswire Amplify™ Next Gen Communications Cloud Cision Communications Cloud® Sign Up Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search ter … first-in-world technology, C-Stem™ and with this now have the first successful application of the 3D format microtissue that delivers efficacy in pre-clinical models. The results speak for themselves with full behavioral recovery observed by 16 weeks after transplantation using the cryopreserved 3D cell format. We look forward to continuing to bring our data to the scientific community as we advance our program" said Kevin Alessandri , Chief Technology Officer, TreeFro … arget="_self">my CNW Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Platform Next Gen Communications Cloud Cision Communications Cloud my CNW 877-269-7890 from 8 AM - 10 PM ET Terms of Use Information Security Policy Site Map Cookie Settings Accessibility Statement Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision co
TreeFrog Therapeutics Secures $75m In Series B Financing To Advance A Pipeline Of Stem Cell-Derived Cell Therapies And Deploy Proprietary C-Stem Technology In The USA & Japan | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
GAIA BioMedicine and TreeFrog Therapeutics Announce Collaboration for the Expansion of Allogeneic NK-like Cells Against Solid Tumors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
DEEPTECH TOUR 2021 - Bordeaux La Tournée 2021 Les Replays Accueil Partenaires Inscription Connexion Ses sessions Retrouvez la liste de toutes les sessions présentées par ce speaker pour ne manquer aucune de ses interventions. Toutes les sessions 8 nov. 15:45 - 17:30 Table ronde - Porteurs de projet et start-up Deeptech : quelles conditions pour se mettre sur la... Jean-Luc Treillou ( Treefrog , co-fondateur et président du CA ) Yann Mondon ( SATT , directeur marketing et comm ) Maylis Chusseau ( SATT Aquitaine ) Toutes les sessions 2021 © Copyright Bpifrance Accessibilité : non conforme Mentio
TreeFrog Therapeutics Secures $75m In Series B Financing To Advance A Pipeline Of Stem Cell-Derived Cell Therapies And Deploy Proprietary C-Stem™ Technology In The USA & Japan Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public C … eased to support TreeFrog Therapeutics in its mission to develop and expand the application for cell therapies. T reeFrog has made tremendous progress in developing C-Stem TM and overcoming many of the bottlenecks in the manufacturing of induced pluripotent stem cells, that will substantially enhance the ability to manufacture cell therapies at scale. We are honored to partner with Kevin, Maxime and Frederic, and a leading group of investors to help accelerate TreeFrog's succ … training. Large Venture – the growth equity arm of Bpifrance – is a $2 billion fund focusing on fast-growing, highly innovative, and capital-intensive startups looking to accelerate organic or external growth. Large Venture has invested in more than 55 companies since 2013 and focuses on life sciences, digital as well as green tech. www.bpifrance.fr About Leonard Green & Partners LGP is a leading private equity investment firm founded in 1989 and based in Los Angeles wit … ndustrials. www.leonardgreen.com About XAnge XAnge is an early-stage investment fund based in Paris and Munich , with €500 million under management. Its investment team supports European entrepreneurs whose aim is to change everyday life through technology, by investing amounts from ranging from €500,000 to €10 million from the seed-funding stage. With an investment policy focused on making technology available to the widest possible audience, XAnge invests in the deep-tech, … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS
Jean-Luc Treillou La Tournée 2021 Les Replays Accueil Partenaires Inscription Connexion JT Jean-Luc Treillou Treefrog co-fondateur et président du CA Ses sessions Retrouvez la liste de toutes les sessions présentées par ce speaker pour ne manquer aucune de ses interventions. Toutes les sessions 8 nov. 10:45 - 11:00 Témoignage – Ma startup Deeptech va changer le monde, découvrez pourquoi ! Jean-Luc Treillou ( Treefrog , co-fondateur et président du CA ) 8 nov. 15:45 - 17:30 Table ronde - Porteurs de projet et start-up Deeptech : quelles conditions pour se mettre sur la... Jean-Luc Treillou ( Tr
TreeFrog Therapeutics SAS - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 TreeFrog Therapeutics SAS Startups | Holding Company | 2018 | France | 100-250 | www.treefrog.fr Startups | Holding Company | 2018 | France | 100-250 | www.treefrog.fr Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Nervous System Diseases Endocrinology and Metabolic Disease Cell therapy Natural Killer Cell Therapies Stem cell therapy Dis … itors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2030. Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identi … lobal Market for iPSCs by Technology 12.3 Global Market for iPSCs by Biomedical Application 12.4 Global Market for iPSCs by Derived Cell Type 12.5 Market Drivers 12.5.1 Current Drivers Impacting the iPSC Market Place 12.6 Market Restraints 13. COMPANY PROFILES For more information about this report visit https://www.researchandmarkets.com/r/pf57qx About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and ma … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Treefrog Therapeutics' Facility to Make Cell Therapy Cheap and Scalable Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? … cures funding for oncology pipeline Treefrog raised a €7M Series A last year to fund the development of its in-house cell therapies, with its lead candidate program for the treatment of Parkinson’s disease at the preclinical stage. This treatment joins dozens of similar programs worldwide, with one of the most advanced being a phase II-stage cell therapy developed by the Australian biotech Living Cell Technologies. “ Cell therapy is most probably going to be a big hit in the
TreeFrog Therapeutics–Desdouits F: management, 202109–202512 CEO before PCAS + Seqens + Pierre Fabre + Bionest Partners RESIGNED 12/25 - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Lau … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events European Spatial Computing Healthcare Summit 2026 Leipzig EUROMAR … holm (NLSDays 2026) BIO-Europe 2026 Cologne (Köln) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
TreeFrog Therapeutics–Irdi Soridec: investment, 201905 financing round Series A totalling €6.5m incl existing seed + co-investor Irdi Soridec - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events European Spatial Computing Healthcare Summit 2026 Leipzig EUROMAR … holm (NLSDays 2026) BIO-Europe 2026 Cologne (Köln) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
#sandiego #biotechnology #bio2024 #businessdevelopment #biotechinnovation #partnerships #celltherapyforall | TreeFrog Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue
TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies Kobe, JAPAN / April 8 th , 2022 – TreeFrog Therapeutics , a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced … em Cell Institute , which was awarded by the prestigious Prix Galien MedStartup Prize in New York . Media Contact TreeFrog Therapeutics Pierre-Emmanuel Gaultier – +33 645 774 258 – [email protected] Discover TreeFrog’s Cell Therapy Programs Discover more Join our Newsletter Stay updated with our latest news and resources Company About TreeFrog About us It’s a Frog’s Life Cell therapies C-Stem™ News & events Become a Froggy Blog Resources Contact ©TreeFr
TreeFrog Therapeutics - Cell & Gene Meeting on the Mesa October 5-7 | Arizona Biltmore Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda A
Coulter Partners Places Industry Veteran Mark Rothera as CEO of TreeFrog Therapeutics | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company Bio … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources Coulter Partners Places Industry Veteran Mark Rothera as CEO of TreeFrog Therapeutics Membe
Mark Rothera Joins TreeFrog Therapeutics as President and CEO | CXO Lanes (UK & Europe) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … s include: • Greater flexibility during clinical development: Manufacturers may apply less stringent quality controls during later, efficacy-focused trials more typical of earlier safety-focused studies and may implement minor changes to production between Phase I and Phase II trials if supported by sufficient data. • More adaptable post-approval controls: For Biologics License Applications (BLAs), the FDA will consider more flexible manufacturing controls, with the option to
Coulter Partners Places Industry Veteran Mark Rothera as CEO of TreeFrog Therapeutics | Coulter Partners Coulter Partners About Solutions Sectors Insight Search website Menu About → Our approach Our team Join the team Diversity, Equity & Inclusion Geographic reach Candidates applications Contact us Solutions → Executive Search Board Advisory Leadership Consulting Sectors → Pharma / Biotech Medtech / Diagnostics Digital Health Agtech & Food production Industrial Biotech Animal Health Patients Services Enabling Services Investors Insight → News Events Close Search Search Close Global (En
Kevin Alessandri & Maxime Feyeux, co-founders of TreeFrog Therapeutics | Maxime Feyeux LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked
Mass-producing iPSC-derived cell therapies while maintaining cell quality – RegMedNet Skip to main content RegMedNet is part of Taylor & Francis Group. Taylor & Francis About us Our journals Our Digital Hubs Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK. Taylor & Francis Home Our journals Our journals Journal content Journal articles Follow us on social media Topics CAR-T Stem cells Cell therapy Gene therapy … The system “inevitably causes genetic alterations,” as recently noted by Nobel Prize winner, Shinya Yamanaka. Overall, 2D platforms are not scalable, therefore limiting batch reproducibility and cost containment. To prepare the commercial phase and address indications requiring a large number of cells, the industry is now moving to bioreactor-based technologies. But here again, the system poses challenges in terms of cell viability and cell quality: with stirred-tank bioreac … es Cell therapy weekly: nanoparticle platform for targeted gene therapy US$7.49 grant awarded to develop off-the-shelf CAR-NKT cell therapy for multiple sclerosis Related tags cell therapy iPSCs Previous article Related articles 25 AUG 2022 NEWS Successful induced pluripotent stem cell-based vaccine created for pancreatic cancer in mouse models 18 JUL 2023 NEWS Brain organoids reveal new treatment strategy for herpes simplex encephalitis 22 FEB 2022 INTERVIEWS Professionalizi … ny Ting 30 MAY 2024 THE WEEK IN CELL THERAPY Cell therapy weekly: US$20 million grant program for advancing cell and gene therapies 1 APR 2021 NEWS New cell therapy approach shows promise for long-term treatment of Type 1 diabetes mellitus 8 MAR 2021 INTERVIEWS Women to Watch: enabling safe and efficient production of cell and gene therapies with Felicia Rosenthal About Advertising & Sponsorship Expert Panel Permissions & content ownership policy Accessibility Edito
Speaker Details | French-American Chamber, New England Our worldwide network Develop your business anywhere in the world with the CCI France International network! 125 chambers in 98 countries Adjust the display Contact us Log in Become a member Search Menu Our Chamber Our Chamber Go to section Who we are Our Missions Board of Directors Team in Boston Contact us More information More information More information More information More information Membership Membership Discover FACCNE's diverse membership options for fostering strong French-American business connections in New England. Join … Institut Curie, Paris , France. He continued his research with a post-doctoral fellowship at the University of Geneva, Switzerland , centered on pluripotent cells, tissue engineering and neurogenerative diseases . Kevin worked for the last 15 years in 3D encapsulation leading to 12 papers more than 1000 citations and filed 14 patents. It was during his time in Geneva that the fortuitous meeting with fellow scientist Maxime Feyeux, led to the subsequent development of a 3D pr … th floor Boston, MA 02109 United States (Access the map) Download CCIFI Connect application Accelerate your business with the 1st private network of French companies in 95 countries: 120 Chambers | 33,000 companies | 4,000 events | 300 committees | 1,200 exclusive privileges Reserved exclusively to members of French CCIs abroad, discover the CCIFI Connect app . Sitemap Privacy Policy FAQ Configure cookies preferences © 2026 French American Chamber of Commerce New England Do y
Jean-Luc Treillou - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Jean-Luc Treillou Co-founder at TreeFrog Therapeutics Jean-Luc Treillou 's Executive Work History Current Co-founder , Co-founder Equilar on 05/17/2026 TreeFrog Therapeutics Chairman , Chairman Equilar on 02/01/2024 TOOPI Organics Past To view Jean-Luc Treillou's complete executive work history, sign up now Education U
Jean-Luc Treillou | CompassList LOG IN Database Startups Founders Investors Insights Trending Bright Ideas Movers and Shakers Failures and Lessons Interviews RESEARCH & ANALYSIS The Big Picture Sector Report SUBSCRIBE ECOSYSTEMS INSIGHTS DATABASE MY FAVORITES STARTUPS FOUNDERS INVESTORS ARTICLES SECTORS TECHNOLOGIES MY PROFILE MANAGE ACCOUNT EMAIL SETTING Log Out Jean-Luc Treillou FOUNDER PROFILE Jean-Luc Treillou Jean-Luc Treillou Founder of TreeFrog Therapeutics LinkedIn Jean-Luc Treillou is co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality p
Press Release : TreeFrog Therapeutics brings in senior profiles to drive the advent of high-quality & affordable allogenic cell therapies - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR Press Release : TreeFrog Therapeutics brings in senior profiles to drive the advent of high-quality & affordable allogenic cell therapies Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-Stem TM technology for cell therapy mass-production … n 2020 research and innovation program through the SME Instrument Phase 2 under grant agreement n° SME 881113. Useful information Press Contact : Pierre-Emmanuel Gaultier, Marketing & Communication Manager +33 6 45 77 42 58, [email protected] Downloads : Download English press release Download French press release Dowload pictures Discover TreeFrog’s Cell Therapy Programs Discover more Join our Newsletter Stay updated with our latest news and resources Company Abou
Things you didn't know about TreeFrog | Jean-Luc TREILLOU LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy … ef MarCom Officer Clément Rieu , Head of Physics R&D Odette Bécheau, Senior Application Scientist #10kfollowers #celltherapyforall Things you didn't know about TreeFrog 15 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 5,763 followers 183 Posts View Profile Connect Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience Recrui
TreeFrog Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas TreeFrog Therapeutics Website: TreeFrog Therapeutics Business Area(s) Cell and Gene Therapy Stem Cells Neurological Disease Cancer Therapeutics Description TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass p
TreeFrog Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & P … 2 9/13/2021 Series B $XXM Subscribe to see more $XXM 0 FY undefined 10 9/5/2019 Grant - IV $XXM Subscribe to see more $XXM 0 FY undefined 10 Date 5/27/2025 5/27/2025 4/23/2024 9/13/2021 9/5/2019 Round Debt Series B - II Corporate Minority Series B Grant - IV Amount $34.1M $XXM $XXM Investors European Investment Bank European Investment Bank Vertex Pharmaceuticals Subscribe to see more Subscribe to see more Valuation $XXM $XXM $XXM $XXM $XXM Revenue 0 FY undefined 0 FY undefin … s 1 Corporate Minority Corporation Massachusetts 3/1/2019 9/13/2021 Bpifrance 3 Grant , Grant - IV (2019) , Series B (2021) Investment Bank France 00/00/0000 00/00/0000 XAnge Subscribe to see more Venture Capital France 00/00/0000 00/00/0000 Leonard Green & Partners Subscribe to see more Private Equity California First funding 5/27/2025 4/23/2024 3/1/2019 00/00/0000 00/00/0000 Last Funding 5/27/2025 4/23/2024 9/13/2021 00/00/0000 00/00/0000 Investor European Investment Ba … reen & Partners Rounds 2 Debt , Series B - II (2025) 1 Corporate Minority 3 Grant , Grant - IV (2019) , Series B (2021) Subscribe to see more Subscribe to see more Board Seats Type Diversified Financial Services Corporation Investment Bank Venture Capital Private Equity Location Luxembourg Massachusetts France France California Learn more by requesting a demo Loading... 498 Seventh Avenue 12th floor New York, NY 10018 [email protected] 212 292 3148 Follow Us On Social A
TreeFrog Therapeutics recruitement - Job offer, internship and volunteering Menu Quick links Homepage All jobs Our selection of training courses Orientation and information Login Find a meaningful job All jobs Create an alert Companies Labels Training for impact Our selection of training courses Be advised Profile My applications My selection My alerts My candidate profile Skills explorer Recruiter Publish a job opening Recruiter space Misc Contact us Découvrez votre profil à impact Mieux comprendre ce que vous recherchez pour trouver un job qui a du sens pour vous. Parcours Orientation Impact
Top 51 Bordeaux Startups to Watch in 2026 Failory Interviews Blog Graveyard Products Subscribe → Download Our List of The Top 100 Accelerators & Incubators This free sheet contains 100 accelerators and incubators you can apply to today, along with information about the industries they generally invest in. Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. Download The List of the 100 Highest-Valued Unicorns This free sheet contains all the information about the top 100 unicorns, including their valuation, HQ's location, founded year, na … iku AI 2023 €1.3M Seed GENIAL AI 2023 €1.8M Seed Meditect Healthcare 2018 $2.4M Grant thinkeo AI 2020 €1M Pre-Seed Poool Marketing 2016 €4.4M Series A Eklo Hotels Travel 2014 €50M Venture Round Starfish Bioscience AgTech 2023 €1.6M Seed Wineriz SaaS 2020 €2M Seed Order1 AI 2023 €670k Venture Round Nurea Healthcare 2018 €1M Seed ALOGIA Groupe Healthcare 2014 €6.5M Venture Round Shiro Games Infrastructure 2012 €50M Private Equity mySofie Sports 2017 €4.2M Series A Netcarbon Mob
Founding publications - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact Founding publications Image: Little bioreactor – TreeFrog Therapeutics Philippe J.R. Cohen, Elisa Luquet, Justine Pletenka, Andrea Leonard, Elise Warter, Basile Gurchenkov, Jessica Carrere, Clément Rieu, Jerome Hardouin, Fabien Moncaubeig, Michael Lanero, Eddy Quelennec, Helene Wurtz, Emilie Jamet, Maelle Demarco, Celine Banal, Paul Van Liedekerke, Pierre Nassoy, Maxime Feyeux, Nathalie Lefort, Kevin Alessandri, Engineering 3D micro-comp
Jobs at TreeFrog Therapeutics | XAnge You are using an outdated browser. Please upgrade your browser to improve your experience and security. Vision Funds Portfolio Team Startup Success Send your pitch Vision Funds Portfolio Team Startup Success Send your pitch Powered by Consider Privacy Terms Follow Us Company Sustainability Press Kit Compliance Resources Knowledge Hub Portfolio Talent Pool LP Access © XAnge 2026 . All rights reserved Legal mentions Privacy Policy Retail funds
Stem Cell Collaboration and Licensing Deals 2010-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert Net … logies Celulas Genetica Censo Biotechnologies Center for iPS Cells Research and Application Centogene Centre for Commercialization of Regenerative Medicine (CCRM) Centre for Drug Research and Development (CDRD) Cephalon Cesca Therapeutics CFD Research CHA Bio & Diostech Charite-Universitatsmedizin Charles River Laboratories ChemDiv Chemizon Children's Hospital Boston Children's Hospital of Orange County Children's Research Institute China Cord Blood China PharmaHub China Sout … aT Pharma Macquarie University Magenta Therapeutics Maryland Stem Cell Research Fund Maryland Technology Development Corporation Massachusetts General Hospital Matricel Maxcyte Mayo Clinic McEwen Centre for Regenerative Medicine McGill University McKesson MD Anderson Cancer Center Medac Medexus Pharmaceuticals Medical College of Wisconsin Medical Research Council Medical Technology Enterprise Consortium Medical University South Carolina Medistem Mekonos Memorial Sloan Ketteri … rker Discovery Stemmatters Stemnion Stempeutics Steven M. Schwartzberg Memorial Fund Stryker Superview Biotechnology Swedish Orphan Biovitrum SwitchGear Genomics Synterys System Biosciences Taconic Biosciences TaiGen Biotechnology TaiRx Takara Bio Takeda Pharmaceutical TAP Biosystems Targazyme Taxus Cardium Pharmaceuticals Technology Strategy Board (UK) Technology University Dresden Teijin Temple University Terumo Blood and Cell Technologies TET Systems Teva Pharmaceutical In … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector T
Cell Therapy Pipeline I iPS-derived Cell Therapies I Allogeneic Stem Cell Therapies --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR The future of cell therapy is here Powered by our C-Stem™ technology, we produce a unique 3D format microtissue for improved efficacy and safety. But first. What is cell therapy ? We all started as small handful of cells and through division, differentiation and growth, we became a human body with an estimated 37.2 trillion cells with many different cell types carrying out specific functions. The bod
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease May 25, 2026 | 4 min read Twitter LinkedIn Facebook Email Print BORDEAUX, France--(BUSINESS WIRE)-- #Bestinclass --TreeFrog Therapeutics, a regenerative medicine biotech compa … for Parkinson's disease is massive. TFG-001 will be ready for a Clinical Trial Application (CTA) in 2027. TreeFrog Therapeutics is exploring co-development and commercialization of TFG-001. To discuss the program further, please attend poster session 3: Time / Date: Wednesday, May 27, 2026 –11:30AM – 1:30PM Location: Hall D-E (3 rd floor) Poster Board: P02.03 Abstract title: Advancing neural microtissues toward a clinically viable cell therapy for Parkinson’s disease About T … of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurospheres for Clinical Application. JPD 12, 871–884. https://doi.org/10.3233/JPD-212934 ii Park, S. et al. Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson’s disease. Cell Stem Cell 31, 25-38.e8. https://doi.org/10.1016/j.stem.2023.11.009 iii Piao, J. et al. Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenito … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developmen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes April 23, 2024 | 4 min read Twitter LinkedIn Facebook Email Print Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that … s, the clear leader in cell therapy for T1D. This is a fantastic opportunity to apply and further develop our C-Stem™ technology for a first-in-class cell therapy treatment which could meet a huge unmet need," said Frédéric Desdouits, Ph.D., CEO of TreeFrog Therapeutics. "This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners … nes on up to two future products and tiered single digit royalties. Vertex will fund all research and development costs related to the collaboration. Vertex will be responsible for all development and commercialization of its cell therapies. About Vertex Visit www.vrtx.com or follow us on LinkedIn , Facebook , Instagram , YouTube and Twitter/X . About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based biotech company set to unlock access to cell therapies for milli … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TREEFROG THERAPEUTICS OPENS TECHNOLOGICAL HUB IN KOBE, JAPAN, TO DRIVE PARTNERSHIPS OPPORTUNITIES IN THE FIELD OF iPSC-DERIVED CELL THERAPIES - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufac … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search TREEFROG THERAPEUTICS OPENS TECHNOLOGICAL HUB IN KOBE, JAPAN, TO DRIVE PARTNERSHIPS OPPORTUNITIES IN THE FIELD OF iPSC-DERIVED CELL THERAPIES April 8, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Within these protective micro-environments, stem cells can achieve optimal growth in large-scale bioreactors, and … l Institute , which was awarded by the prestigious Prix Galien MedStartup Prize in New York . Media Contact Pierre-E Gaultier TreeFrog Therapeutics + 33 6 45 77 42 58 [email protected] Twitter LinkedIn Facebook Email Print LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy June 26, 2026 · 4 min read · Heather McKenzie Layoff Trac … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TreeFrog Therapeutics Enters Into Pioneering Research Collaboration in Immuno-Oncology With the University of Pittsburgh - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TreeFrog Therapeutics Enters Into Pioneering Research Collaboration in Immuno-Oncology With the University of Pittsburgh October 24, 2024 | 2 min read Twitter LinkedIn Facebook Email Print BORDEAUX, France--(BUSINESS WIRE)-- #CellTherapy --TreeFrog Therapeutics has announced a research collaboration with … lls. “ We are delighted to embark on this collaboration with Professor Bruno to apply our encapsulation technology to further understand and work with TLS, bringing new levels of control over the microenvironment of these amazing 3D immune structures. Research indicates that the presence of TLS in cancer may boost anti-tumor immunity and improve responses and prognosis, so I am excited to work with Professor Bruno and her team to explore synergies and opportunities of our 3D … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth December 16, 2025 | 2 min read Twitter LinkedIn Facebook Email Print BORDEAUX, France--(BUSINESS WIRE)-- #CellTherapyForAll --Tree … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TreeFrog Presents Data From Their Parkinson's Cell Therapy Program at the American Academy of Neurology Annual Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search TreeFrog Presents Data From Their Parkinson’s Cell Therapy Program at the American Academy of Neurology Annual Meeting April 15, 2024 | 2 min read Twitter LinkedIn Facebook Email Print TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson’s Disease is presenting for the first time … first-in-world technology, C-Stem™ and with this now have the first successful application of the 3D format microtissue that delivers efficacy in pre-clinical models. The results speak for themselves with full behavioral recovery observed by 16 weeks after transplantation using the cryopreserved 3D cell format. We look forward to continuing to bring our data to the scientific community as we advance our program" said Kevin Alessandri, Chief Technology Officer, TreeFrog Thera … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace is the digital hub for life science news and jobs. We provide essential insights, o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH October 11, 2022 | 4 min read Twitter LinkedIn Facebook Email Print For pathfinders in cell and gene therapy striving to accelerate next-generation care, Invetech delivers robust, scalable and cost-eff … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TREEFROG THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD TO GUIDE THE DEVELOPMENT OF PROPRIETARY IPS PLATFORM & CELL THERAPY PIPELINE - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search TREEFROG THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD TO GUIDE THE DEVELOPMENT OF PROPRIETARY IPS PLATFORM & CELL THERAPY PIPELINE March 1, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created … n biophysics. From 1999 to 2012, he worked at the Institut Curie - led by Nobel Prize laureate Pierre-Gilles de Gennes -, where he developed an expertise in lipid membrane physics, cell mechanics, as well as microfluidic and optomechanical devices for biology. Supervising the thesis of TreeFrog Therapeutics’ co-founder Kevin Alessandri, he co-invented the C-StemTM technology. Since 2012, leading a team in Bioimaging & Optofluidics in Bordeaux, Pierre Nassoy has focused hi … veries of 2016, and she received various awards including the International 3Rs Prize. In 2020, she established her own group at the MRC Laboratory of Molecular Biology in Cambridge, UK, intending to understand how tissue organization modulates pluripotent stem cell identity and differentiation during mouse and human embryo development. About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TREEFROG THERAPEUTICS LAUNCHES A $100,000 RESEARCH GRANT IN REGENERATIVE MEDICINE - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cance … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search TREEFROG THERAPEUTICS LAUNCHES A $100,000 RESEARCH GRANT IN REGENERATIVE MEDICINE April 19, 2022 | 3 min read Twitter LinkedIn Facebook Email Print The Stem Cell Spaceshot Grant is open to PhD-level scientists and PhD students conducting research in stem cell biology, biophysics, gene editing, cell therapy, and bioprodu … otent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem cell biology and regenerative medicine. The Stem Cell Spaceshot Grant is open to PhD-level scientists and PhD students conducting research in stem cell biology, biophysics, gene editing, cell therapy, and bioproduction engineering. With this grant, TreeFrog Therapeutics aims at supporting scientific discoveries with therapeutic impact in 4 ar … aftment, integration and long-term survival of stem-cell derived transplants To apply, researchers only need to submit an email, a one-page research project description and a graphical abstract through an online form available on the TreeFrog Therapeutics’ website. Applications will be opened from May 1st to June 30th 2022. 10 nominees will be selected in August 2022. The winner will be awarded in October 2022 following interviews with an interdisciplinary jury composed of wo … iscoveries that will shape the future of regenerative medicine. We designed the grant that we would have liked to apply to: the application process is simple, fast and anonymous - so that it is ideas, rather that resumes that are awarded –, no cumbersome reporting is required, and the intellectual property of scientists is preserved. I can’t wait
Big Day for Four Biopharmas Who Net Millions in Add-on Funds - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rele … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Big Day for Four Biopharmas Who Net Millions in Add-on Funds September 14, 2021 | 3 min read | Mark Terry Twitter LinkedIn Facebook Email Print Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look. Several biopharma compan … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TREEFROG THERAPEUTICS EXPANDS BOARD WITH NEW INDEPENDENT MEMBERS FROM THE CELL THERAPY INDUSTRY - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search TREEFROG THERAPEUTICS EXPANDS BOARD WITH NEW INDEPENDENT MEMBERS FROM THE CELL THERAPY INDUSTRY April 14, 2022 | 4 min read Twitter LinkedIn Facebook Email Print Following our Series B, we welcomed new investors to our board: Bpifrance Large Venture, Leonard Green & Partners, and Bristol Myers Squibb. I am delighted … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TreeFrog Therapeutics Secures $75m In Series B Financing To Advance A Pipeline Of Stem Cell-Derived Cell Therapies And Deploy Proprietary C-Stem™ Technology In The USA & Japan - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Se … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search TreeFrog Therapeutics Secures $75m In Series B Financing To Advance A Pipeline Of Stem Cell-Derived Cell Therapies And Deploy Proprietary C-Stem™ Technology In The USA & Japan September 13, 2021 | 8 min read Twitter LinkedIn Facebook Email Print TreeFrog Therapeutics, a privately held French-based biotech startup fo … eased to support TreeFrog Therapeutics in its mission to develop and expand the application for cell therapies. T reeFrog has made tremendous progress in developing C-Stem TM and overcoming many of the bottlenecks in the manufacturing of induced pluripotent stem cells, that will substantially enhance the ability to manufacture cell therapies at scale. We are honored to partner with Kevin, Maxime and Frederic, and a leading group of investors to help accelerate TreeFrog's succ … training. Large Venture – the growth equity arm of Bpifrance – is a $2 billion fund focusing on fast-growing, highly innovative, and capital-intensive startups looking to accelerate organic or external growth. Large Venture has invested in more than 55 companies since 2013 and focuses on life sciences, digital as well as green tech. www.bpifrance.fr About Leonard Green & Partners LGP is a leading private equity investment firm founded in 1989 and based in Los Angeles wit … ndustrials. www.leonardgreen.com About XAnge XAnge is an early-stage investment fund based in Paris and Munich , with €500 million under management. Its investment team supports European entrepreneurs whose aim is to change everyday life through technology, by investing amounts from ranging from €500,000 to €10 million from the seed-funding stage
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
RIFF��WEBPVP8 ��p�*�,>�H�L%�"�"r��� gi��N�ܲA�7�p� �|�zO��ۏ��⟠����?�}R����Q������̭ >�xPn��aw��x_����7�[����m���������R��|�����Ό8ps`�r�8�(�΄R5���r��@��S�n�S��c���Hi�=�� �K��[�����cg������$W:`�&d�!� ʡ��Fd��6f���B;jr;6jX������ �: C��p�Nxv���g� IK�C��y���d ��[̧cG ��2� ��'�)# ���*[Z5 ��M�(�Ѭ�9� �6A��̋�nD_�/���\.>��N��Nߩ���h�Ĭ�ȯѤQl�����}�o��sd�\A����?1?P7����Iڿ� �~���*/����/7��^��舤�h�Fc��p�E��k>�k@2��!�Ȏ 0J�#��4]��Q��#��?�CW�A�����cO(R���������螇�����e�~�g�"� Ө'O�N;�S�>HH� g�N��N /!�z�0 ��T��趵�� ��b�d�{���X��g.�~+ �-`�ꎟ� �g��9߷*Ј����3��LJ��c�"ѱ�� ����G�;]�m)o��
Peter Nell joins TreeFrog Therapeutics as Independent Board Member - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR Peter Nell joins TreeFrog Therapeutics as Independent Board Member Bordeaux, France / July 7th, 2022 – Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell & gene therapy field over the past ten years and is currently building a new gene editing biotech company. He has worked fo
CP Scorecard | Largest Pharma & Biotech Deals Since 2017 CP Scorecard | Largest Pharma & Biotech Deals Since 2017 Best Practice for Dealmakers in the Life Sciences Log In Home Dealmaking Reports Annual Subscription CP Knowledge Centre: More Info CP Knowledge Centre: Therapy reports CP Knowledge Centre – Stage development reports – Demonstration CP Knowledge Centre – Technology type reports – Demonstration CP Knowledge Centre – Industry type reports – Demonstration CP Knowledge Centre – Deal type reports – Demonstration Subscriber login Subscription options CP Scorecar … ement Overview Earendil Labs announced a strategic collaboration with Sanofi to apply Earendil’s discovery platform to multiple autoimmune and inflammatory disease programs . The collaboration is focused on the discovery of bispecific antibody candidates . Sanofi will lead development and worldwide commercialization of bispecific candidates arising from the collaboration. The transaction is subject to customary closing conditions . Financial Terms Earendil Labs will receive u … rategic / Development Rationale or Impact The collaboration enables Earendil to apply its platform to a broader set of autoimmune targets and aims to improve the efficiency and precision of discovering and optimizing bispecific antibody candidates. Sanofi’s role in clinical development and global commercialization is intended to accelerate translation of candidates into potential medicines for autoimmune diseases. Product / Technology / Context Earendil’s platform is describe … evelopment of disease-modifying therapies , which are currently lacking Expands application of somatic genomics to immunology and chronic disease Product / Technology / Context Platform analyzes somatic genetic mutations in patient tissues Identifies mutations that cause or protect against disease Integrates genomics and computational technologies Designed to inform target discovery across multiple therapeutic areas Applied to IBD, a chronic inflammatory disease affecting mil … n portfolio, alongside a planned collaboration with Galapagos to co-develop and fund the acquired assets. Agreement Overview Definitive agreement for Gilead Sciences to acquire Ouro Medicines Adds OM336 (gamgertamig) , a BCMAxCD3 bispecific T cell engager, to Gilead’s pipeline Focus on autoimmune and inflammatory diseases , including AIHA and ITP
Vertex enlists TreeFrog in $780M deal to scale up cell therapies for type 1 diabetes | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
You need to enable JavaScript to run this app. Loading...
Green treefrog enjoying summer at... - Friends of Radnor Lake Facebook Log In Friends of Radnor Lake's Post Friends of Radnor Lake June 8, 2025 · Shared with Public Green treefrog enjoying summer at Radnor Lake! #ratherbeatradnor Photo by Steve Ward All reactions: 102 4 comments Like Comment Most relevant Abbey Craun Okay to share if I credit Steve? 1y 1 Author Friends of Radnor Lake Abbey Craun Yes! Thank you for crediting Steve. 1y SueAnn Norris So cute! 1y Top fan Carol King Holland 1y
vrtx-20250403 DEF 14A VERTEX PHARMACEUTICALS INC / MA 0000875320 FALSE iso4217:USD 0000875320 2024-01-01 2024-12-31 0000875320 vrtx:ReshmaKewalramaniMember 2024-01-01 2024-12-31 0000875320 vrtx:ReshmaKewalramaniMember 2023-01-01 2023-12-31 0000875320 2023-01-01 2023-12-31 0000875320 vrtx:ReshmaKewalramaniMember 2022-01-01 2022-12-31 0000875320 2022-01-01 2022-12-31 0000875320 vrtx:ReshmaKewalramaniMember 2021-01-01 2021-12-31 0000875320 2021-01-01 2021-12-31 0000875320 vrtx:ReshmaKewalramaniMember 2020-01-01 2020-12-31 0000875320 vrtx:JeffreyLeidenMember 2020-01-01 2020-12-31 0000875320 2020-0 … strant as Specified In Its Charter) Payment of Filing Fee (Check all boxes that apply): x No fee required. o Fee paid previously with preliminary materials. o Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.   A Letter from our Executive Chairman and Chief Executive Officer Dear Shareholders: 2024 marked a year of tremendous growth for Vertex and excellent performance across the business, with our commercial, research & … isory vote on our 2024 named executive officer compensation; and • on one proposal submitted by a shareholder, if properly presented at the meeting. Shareholders also will transact any other business that may properly come before the annual meeting or any adjournment or postponement of the annual meeting. MEETING INFORMATION PROXY MATERIALS: We are using the “Notice and Access” method of providing proxy materials to you via the Internet. We are mailing to yo … BLE TO PARTICIPATE IN THE MEETING ONLINE, VOTE YO UR SHARES ELECTRONICALLY, AND SUBMIT YOUR QUESTIONS DURING THE MEETING BY VISITING HTTPS://MEETNOW.GLOBAL/MXD5MZM. THERE IS NO PHYSICAL LOCATION FOR THE ANNUAL MEETING. Shareholders will need their unique control number, which appears on the Notice of Internet Availability of Proxy Materials or proxy card (printed in the shaded bar), or within the body of the email sending the proxy statement. If you hold shares beneficia … oker or other nominee. Once you have received a legal proxy from them, you must submit a copy of this legal proxy, along with your name and email address to Computershare at [email protected]. Alternatively, you may mail your legal proxy to the following address: Computershare, Vertex Pharmaceuticals Incorporated Legal Proxy, P.O. Box
VERTEX TREEFROG THERAPEUTICS CONCLUT UN ACCORD STRATEGIQUE ET DE LICENCE AVEC L'AMERICAIN VERTEX PHA BLOGS BÖRSENLEXIKON RSS WATCHLIST News Suche Menü ein-/ausblenden Blogs Bilder News NEWS AKTIENKURSE BÖRSE WIRTSCHAFT POLITIK SPORT UNTERHALTUNG WISSENSCHAFT AUSLAND POLIZEI INTERNATIONAL SONSTIGE NEWS AKTIENKURSE BÖRSE WIRTSCHAFT POLITIK SPORT UNTERHALTUNG WISSENSCHAFT AUSLAND POLIZEI INTERNATIONAL SONSTIGE BLOGS KALENDERBLATT NEWSLETTER BÖRSENLEXIKON RSS WATCHLIST News Suche Menü ein-/ausblenden Blogs Bilder News Unterrubriken AD HOC MITTEILUNGEN ANALYSTENSTIMMEN CORPORATE NEWS DIRECTORS' DEA
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
%PDF-1.7 %���� 1 0 obj >/Metadata 156 0 R/ViewerPreferences 157 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 21 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��=�n$���� �hP6�@(@]� /����{0|�9y�;{��/�d��LFv�%xMK��A2ޯ ��ߝ~����ϟ���S���o�?��%q�'-�"���hs���ϟ��_O"���;�3��� ����KN?�B����?��7�������>zI���ϟލ�s���������".J��U�p߃�(��g�������t�*���Y���WbBC� �oQ>66] ��/�;�S� ~�+��g�.)~P��oP� ^ֻ ���y�&�`�ׂ�*�x&�X0�?_�.��܉��c�]��Gm/�-�>6]�u��������s�Hc���X��L�[
Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology | Umoja Biopharma Skip to content Our Company Leadership Board of Directors Advisory Board Investors Our Science Overview Manufacturing Our Pipeline News + Resources Press Releases Presentations + Publications Careers Contact Our Company Our Science Overview Manufacturing Our Pipeline News + Resources Press Releases Presentations Careers Contact Accessibility Privacy Policy Transparency in Coverage Sitemap Umoja Biopharma and TreeFrog Therapeutic
IPS-derived Cell Therapy News - TreeFrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR Our latest news & events Discover our latest updates below! Latest News News Events Press Others View all TFG‑001: 3D Neural Microtissue Cell Therapy for Parkinson’s Disease: new preclinical data presented at the 7th World Parkinson Congress in Phoenix, Arizona TFG‑001: 3D Neural Microtissue Cell Therapy for Parkinson’s Disease: new preclinical data presented at the 7th World Parkinson Congress in Phoenix, Arizona TreeFrog Ma … ANNUAL MEETING TreeFrog July 9, 2024 TreeFrog Therapeutics Picks-Up Best Poster Award At The International Society For Cell & Gene Therapy (ISCT) Annual Meeting For Their Cell Therapy Program In Parkinson’s Disease TreeFrog Therapeutics Picks-Up Best Poster Award At The International Society For Cell & Gene Therapy (ISCT) Annual Meeting For Their Cell Therapy Program In Parkinson’s Disease TreeFrog May 29, 2024 TreeFrog Presents Data From Their Parkinson’s Disease Ce … . TreeFrog December 7, 2021 TreeFrog Therapeutics Awarded the Galien MedStartup Prize 2020 for its International Consortium on iPSC Quality with US, Japan & France TreeFrog October 28, 2021 TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies and deploy proprietary C-Stem™ technology in the USA & Japan TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affor … 12, 2021 TreeFrog Therapeutics（仏国ボルドー）、iPS細胞の品質に関する国際コンソーシアムでGalien MedStartup Prizeを受賞 TreeFrog January 29, 2021 The French Blood Agency announces agreement with TreeFrog Therapeutics to scale-up manufacturing of iPS-derived hematopoietic stem cell transplants TreeFrog November 17, 2020 Presenting our cell therapy program for Parkinson’s disease at Nectar 2020 ! TreeFrog November 11, 2020 TreeFrog Therapeutics and Invetech expand partnership to transition high-through … ring TreeFrog October 7, 2020 TreeFrog nominated for the Prix Galien MedStartup Award ! TreeFrog September 22, 2020 TreeFrog joins the Japanese Society for Regenerative Medicine TreeFrog June 18, 2020 360° video of our first industrial site ! TreeFrog June 10, 2020 Press Release : TreeFrog Therapeutics opens its first facility dedicated to iPS ce
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Relea … s, the clear leader in cell therapy for T1D. This is a fantastic opportunity to apply and further develop our C-Stem™ technology for a first-in-class cell therapy treatment which could meet a huge unmet need," said Frédéric Desdouits, Ph.D., CEO of TreeFrog Therapeutics. "This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners … nes on up to two future products and tiered single digit royalties. Vertex will fund all research and development costs related to the collaboration. Vertex will be responsible for all development and commercialization of its cell therapies. About Vertex Visit www.vrtx.com or follow us on LinkedIn , Facebook , Instagram , YouTube and Twitter/X . About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based biotech company set to unlock access to cell th … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes – Vertex obtains an exclusive license to TreeFrog’s C-Stem TM technology in Type 1 diabetes – – TreeFrog and Vertex to collaborate on scale-up of … s, the clear leader in cell therapy for T1D. This is a fantastic opportunity to apply and further develop our C-Stem™ technology for a first-in-class cell therapy treatment which could meet a huge unmet need,” said Frédéric Desdouits, Ph.D., CEO of TreeFrog Therapeutics. “This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners … nes on up to two future products and tiered single digit royalties. Vertex will fund all research and development costs related to the collaboration. Vertex will be responsible for all development and commercialization of its cell therapies. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multip
Life at TreeFrog - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR Life at TreeFrog Find out what it takes to become part of TreeFrog Explore TreeFrog values Do you feel connected to the core values of TreeFrog #Do Since the beginning we focus on trying to make it simple. We recruit doers that are passionate about advancing cell therapies together. #Trust Our purpose “Cell Therapy for all” means that our business is about being entrusted by a large array of stakeholders. Maintaining a culture of trust is the
Jobs Archives - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR Discover TreeFrog’s Cell Therapy Programs Discover more Join our Newsletter Stay updated with our latest news and resources Company About TreeFrog About us It’s a Frog’s Life Cell therapies C-Stem™ News & events Become a Froggy Blog Resources Contact ©TreeFrog, 2026. All rights reserved. General Conditions of Use Cookie Policy (EU) Manage Consent To provide the best experiences, we use technologies like cookies to store and/or access d
Become a Froggy - Treefrog Therapeutics --> Cell therapies C-Stem™ About us It’s a Frog’s Life News & events Become a Froggy Resources Contact EN FR Become a Froggy Find out what it takes to become part of TreeFrog Our jobs Apply today ! On this site you can directly see the current open positions. However, if your perfect job is not there but you are interested in becoming a Froggy, you can also submit your resume and why you are motivated to join us here. See open positions Our Journey An ecosystem of talent at the frontiers of physics & biology TreeFrog Therapeutics has a clear purp … tribute, help or understand. Our recruitment process Finding the perfect froggy Submit your application online. If you are shortlisted, you will have a first discussion with the HR team (Ines or Charlene) so we can get to know more about you and you about us! Bravo! At this stage, you will have a face-to-face or video interview with the hiring manager and a member of the HR team. Nearly there! The final candidates come to our site for a half day to meet various members of the
The talent behind cell therapy | TreeFrog Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy … . - Innovation: The intersection of biotechnology, bioengineering, and clinical application. - Impact: Shifting the healthcare paradigm from management to true regeneration. Check out this incredible look at how far the science has come: https://lnkd.in/ggJZ_BiA What do you see as the biggest breakthrough on the horizon for regenerative medicine? Let's discuss in the comments. 👇 #StemCells #RegenerativeMedicine #Biotech #HealthcareInnovation #FutureOfMedicine …more Welcome t … way. One way to visualize this is through Waddington’s landscape - like a ball rolling down a hill, where each dip, turn, or obstacle represents a decision point guiding the cell toward becoming more specialized. What makes this idea so compelling is how it brings together complexity and simplicity. From a single cell at the very beginning of life to the trillions of specialized cells in the human body, development is not a straight path, it is shaped by context, signals, an
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Plasmid DNA Manufacturing Market to Reach $20.21 BN by 2034 | Linke Wire posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you ag … help you to: • understand differences in hcDNA reporting across the industry • apply a standardized approach by normalizing hcDNA levels to AAV genomes (vg) • use a reference range for vg-normalized hcDNA to support risk assessment and product comparisonThese resources explore key considerations for impurity management, including risk assessment, analytical strategies and regulatory expectations, helping the industry move toward greater consistency and clarity. If you’d like
Press Releases | Coulter Partners Coulter Partners About Solutions Sectors Insight Search website Menu About → Our approach Our team Join the team Diversity, Equity & Inclusion Geographic reach Candidates applications Contact us Solutions → Executive Search Board Advisory Leadership Consulting Sectors → Pharma / Biotech Medtech / Diagnostics Digital Health Agtech & Food production Industrial Biotech Animal Health Patients Services Enabling Services Investors Insight → News Events Close Search Search Close Global (English) Our approach Our team Join the team Diversity, Equity & Incl
2025 CDMO Market Update: BioDlink Sets ADC Benchmark | Joseph O'Grady posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a … help you to: • understand differences in hcDNA reporting across the industry • apply a standardized approach by normalizing hcDNA levels to AAV genomes (vg) • use a reference range for vg-normalized hcDNA to support risk assessment and product comparisonThese resources explore key considerations for impurity management, including risk assessment, analytical strategies and regulatory expectations, helping the industry move toward greater consistency and clarity. If you’d like
Treefrog evolves to support other local and international startups | Financial Post Advertisement oop Story continues below This advertisement has not loaded yet, but your article continues below. Skip to Content Challenge your brain with PUZZMO's daily puzzles. Start playing >> Challenge your brain with PUZZMO's daily puzzles. Start playing >> Sections Search Search financialpost.com Perform search Share Share this Story : Financial Post Copy Link Email X Reddit Pinterest LinkedIn Tumblr Subscribe for $0.99/week User My Account Subscribe for $0.99/week Search financialpost.com Perform search
Nicholas Green | Coulter Partners Coulter Partners About Solutions Sectors Insight Search website Menu About → Our approach Our team Join the team Diversity, Equity & Inclusion Geographic reach Candidates applications Contact us Solutions → Executive Search Board Advisory Leadership Consulting Sectors → Pharma / Biotech Medtech / Diagnostics Digital Health Agtech & Food production Industrial Biotech Animal Health Patients Services Enabling Services Investors Insight → News Events Close Search Search Close Global (English) Our approach Our team Join the team Diversity, Equity & Incl
TreeFrog Therapeutics Names Mark Rothera as CEO | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe Now Stay informed! Su
TreeFrog leaps to $75m series B - Global Venturing Global Venturing | TreeFrog leaps to $75m series B Where Global Innovation and Capital Meet Home --> Register Login Go Corporate University Impact Full Site Corporate University Impact Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent … bb helped the cell encapsulation technology developer raise cash that will help fund its international growth. --> TreeFrog Therapeutics, a France-based stem cell therapy developer advancing research from Digital Photonics and Nanoscience Laboratory (LP2N), completed a $75m series B round yesterday featuring pharmaceutical firm Bristol Myers Squibb. The round was led by BPIfrance’s Large Venture fund and included investment firm Leonard Green & Partners and XAnge, the ven
Alumni - La Synapse Skip to main content Close Search Menu search Menu Homepage La Synapse Learn more about La Synapse Column About La Synapse Our team Our programs Our geographic locations Our thematic competencies Column About La Synapse The Office for Science and Technology Science & tech francophile network Follow us on LinkedIn Column Useful links Our partners Testimonials and alumni Contact us Our programs Column #1 NETVA Start in America Column #1 Start in France Column #1 Innovation Days Column #4 Learning Expedition Our footprint La Synapse, nine key locations Column Our location
TreeFrog Therapeutics opens its first facility dedicated to iPS cell therapy scale-up in Bordeaux, France - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business TreeFrog Therapeutics opens its first facility dedicated to iPS cell therapy scale-up in Bordeaux, France June 10, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Reaching a new milestone in the industrial implementation of the C-StemTM technology, TreeFrog Therapeutics announces the … n 2020 research and innovation program through the SME Instrument Phase 2 under grant agreement n° SME 881113. Press contact Pierre-Emmanuel Gaultier, Marketing & Communication Manager [email protected] + 33 6 450 600 49 ________________________________________________________________ View 360° video Download picture Twitter LinkedIn Facebook Email Print Real estate Europe LATEST Duchenne muscular dystrophy Capricor thrown for another l … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin